The 2014 BIO International Convention, where the global biotech community meets, connecting the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feeding the world, concluded today at the San Diego Convention Center with a record number of partnering meetings. Hosted by the Biotechnology Industry Organization (BIO), the event drew 15,667 industry leaders, including nearly 2,500 CEO’s, from 50 states and 70 countries.Continue reading
Category Archives: AZBio News
Regenesis Biomedical Releases Educational Video on Provant Methodof Action
Provant Therapy Mechanism of Action Video Animation Now Available
Life science laboratory research shows Provant treats pain two ways
Scottsdale, Arizona, June 27, 2014 — Regenesis Biomedical Inc., today announced the release of an animation on the Provant Therapy System’s mechanism of action. This video shows how Provant treats pain two ways: anti-nociceptive analgesia, and anti-inflammatory.
Pain management and the treatment of inflammation are important considerations following operative procedures. Persistent pain may lead to reduced physical function and sense of well-being, increased consumption of opioid analgesics, and expensive, invasive ancillary procedures (including hospital readmissions, repeat surgeries, extended physical therapy, lab tests, radiology, epidural injections, and implantation of spinal cord stimulators and intrathecal drug pumps).
“Post-op pain is often undermanaged, and narcotic use continues to rise,” said Scott Brooks, President and Chief Executive Officer of Regenesis Biomedical. “Regenesis’ life science research further validates the pain relief effect seen in Provant patients. As an alternative treatment, Provant may allow patients to avoid expensive procedures, reduce opioid consumption, and avoid opioid negative side effects.”
The video may be viewed at http://www.regenesisbio.com/our-videos.php
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on the research, design, manufacture, and sale of energy-based medical products and services that alleviate pain, restore health, and improve quality of life. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities and providers that serve patients treated in acute care hospitals, long-term care, outpatient clinics, and home care.
About the Provant®
Therapy System Provant uses pulsed electromagnetic energy to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues. Provant relieves pain two ways: through anti-nociceptive analgesia by inducing endogenous opioids, and by regulating inflammatory mediators.
Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesisbio.com
480-970-4970 phone
SOURCE: Regenesis Biomedical Inc.
Life Science Companies are Two of Six Arizona Innovation Challenge Winners
Six early-stage companies, including two life science companies, were announced winners Wednesday in the Arizona Commerce Authority’s Spring 2014 Arizona Innovation Challenge.Continue reading
Managing specialized microbes to clean stubborn chemicals from the environment
Chlorinated chemicals perform a host of societally useful functions, but they also have a dark side. Once their use life has ended, such agents often become environmental contaminants, sometimes resistant to bioremediation.Continue reading
InVivo Therapeutics announces second Arizona Based Clinical Trial Site
InVivo Therapeutics Announces Barrow Neurological Institute As Third Clinical Trial Site for Neuro-Spinal ScaffoldContinue reading
BIO BizLink streamlines CROs, CMOs and regulatory consultant search and evaluation
Merz to Acquire Ulthera for $600M
MERZ TO ACQUIRE ULTHERA, INC., A LEADING ENERGY DEVICE COMPANY IN THE AREA OF NON-SURGICAL LIFTContinue reading
2014 Life Sciences Workforce Trends Report Released at BIO.
The Coalition of State Bioscience Institutes (CSBI) Releases the 2014 Life Sciences Workforce Trends Report at BIO. Key Findings Support Industry Hiring Demand with a Strong Need for Knowledge‐Based Employees.
Calimmune (Tucson, AZ) Approved to Treat Second Group in HIV Stem Cell Gene Modification Study
June 25, 2014
San Diego, CA – Calimmune today announced encouraging safety data from its innovative gene-based stem cell therapy, Cal-1-being developed to help cure individuals infected with HIV. The company can now begin treating the second group of patients in the trial, which is being funded in part by a grant from the California Institute for Regenerative Medicine (CIRM).Continue reading